Yak interferon-alpha loaded solid lipid nanoparticles for controlled release.
To explore the potential of a novel animal interferon formulation for controlled release, the yak interferon-alpha (IFN-alpha) glutathione S-transferase (GST) fusion protein was expressed in Escherichia coli (E. coli) and the purified recombinant IFN-alpha was encapsulated into solid lipid nanoparticles (SLN) by double emulsion solvent evaporation (w/o/w) method. The particle size and zeta potential of IFN-alpha-loaded SLN were 124.2+/-10.2 nm and -11.2+/-0.6 mV. The encapsulation efficiency of IFN-alpha and loading capacity of the SLN were 83.7+/-4.5% and 1.73+/-0.15%, respectively. In vitro release study and antiviral assay demonstrated that the IFN-alpha released from the SLN in a 16-day period exhibited antiviral activity in Madin-Darby bovine kidney (MDBK) cells against vesicular stomatitis virus (VSV), and showed a release pattern of an initial burst release followed by a sustained and slow release. Cytotoxicity assay in cell culture demonstrated that the SLN were not toxic. The results of this exploratory study suggest that the IFN-alpha-loaded SLN could be a useful formulation for controlled release in veterinary therapeutics.
Li
Shaoyong
S
Department of Preventive Veterinary Medicine, College of Veterinary Medicine, China Agricultural University, Beijing 100193, PR China.
Zhao
Baokai
B
Wang
Fenghua
F
Wang
Ming
M
Xie
Shuyu
S
Wang
Siliang
S
Han
Chao
C
Zhu
Luyan
L
Zhou
Wenzhong
W
D000818:Animals; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000302:isolation & purification / Q000627:therapeutic use; D019556:COS Cells; D002417:Cattle; D002418:Cattle Diseases / Q000188:drug therapy; D002522:Chlorocebus aethiops; D003692:Delayed-Action Preparations / Q000627:therapeutic use*; D005982:Glutathione Transferase / Q000378:metabolism; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000302:isolation & purification / Q000627:therapeutic use; D053758:Nanoparticles / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D018116:Vesiculovirus / Q000187:drug effects
D000998:Antiviral Agents; D003692:Delayed-Action Preparations; D016898:Interferon-alpha; D011993:Recombinant Fusion Proteins; D005982:Glutathione Transferase